EBITDA Margin % is calculated as EBITDA divided by its Revenue. Pyxis Oncology's EBITDA for the
three
months ended in Dec. 2023 was $-17.08 Mil. Pyxis Oncology's Revenue for the
three
months ended in Dec. 2023 was $0.00 Mil. Therefore, Pyxis Oncology's EBITDA margin for the quarter that ended in Dec. 2023 was 0.00%.
Pyxis Oncology EBITDA Margin % Historical Data
The historical data trend for Pyxis Oncology's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pyxis Oncology's EBITDA Margin %
For the Biotechnology subindustry, Pyxis Oncology's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pyxis Oncology's EBITDA Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pyxis Oncology's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Pyxis Oncology's EBITDA Margin % falls into.
Pyxis Oncology EBITDA Margin % Calculation
EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.
Pyxis Oncology's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Pyxis Oncology EBITDA Margin % Related Terms
Thank you for viewing the detailed overview of Pyxis Oncology's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Pyxis Oncology (Pyxis Oncology) Business Description
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve the quality of life for patients. It develops the product candidates to directly kill tumor cells and address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its lead ADC product candidate is PYX-201, an investigational human IgG1 isotype site-specifically conjugated with an auristatin toxin targeting EDB that initially develop for solid tumors, including NSCLC, hormone receptor-positive breast, ovarian and thyroid cancer. The IO product candidate is PYX-106, designed to block Siglec-15-mediated suppression of T-cell proliferation and function.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PYXS has been successfully added to your 